<code id='2A89D7B83F'></code><style id='2A89D7B83F'></style>
    • <acronym id='2A89D7B83F'></acronym>
      <center id='2A89D7B83F'><center id='2A89D7B83F'><tfoot id='2A89D7B83F'></tfoot></center><abbr id='2A89D7B83F'><dir id='2A89D7B83F'><tfoot id='2A89D7B83F'></tfoot><noframes id='2A89D7B83F'>

    • <optgroup id='2A89D7B83F'><strike id='2A89D7B83F'><sup id='2A89D7B83F'></sup></strike><code id='2A89D7B83F'></code></optgroup>
        1. <b id='2A89D7B83F'><label id='2A89D7B83F'><select id='2A89D7B83F'><dt id='2A89D7B83F'><span id='2A89D7B83F'></span></dt></select></label></b><u id='2A89D7B83F'></u>
          <i id='2A89D7B83F'><strike id='2A89D7B83F'><tt id='2A89D7B83F'><pre id='2A89D7B83F'></pre></tt></strike></i>

          explore

          explore

          author:fashion    Page View:962
          IQVIA signage. -- health tech coverage from STAT
          Adobe

          The health data giant IQVIA became a dominant force by gobbling up its rivals. Over decades, it feasted on upstarts with new datasets or novel technologies, growing into a juggernaut with no peer in the business of brokering Americans’ medical information.

          Now, government regulators say, IQVIA’s appetite for acquisition is getting out of control — and must be reined in.

          advertisement

          A Federal Trade Commission lawsuit seeking to block its acquisition of the digital advertising firm DeepIntent marks a crossroads for the company and the multi-billion dollar medical advertising economy it serves. The agency, which is seeking an injunction and temporary restraining order in federal court, argues that IQVIA’s data vault has become so large — and revealing — that it forms the substrate of an entire industry focused on showering doctors and patients with marketing messages.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          focus

          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more
          With trial win, GSK could get blood cancer drug back on market
          With trial win, GSK could get blood cancer drug back on market

          JUSTINTALLIS/AFPviaGettyImagesLONDON—TheresurrectionofaGSKbloodcancerdrug—whichthecompanywithdrewfro

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          ASCO: AstraZeneca's hat trick, and palliative care's spotlight

          "Arrestingcancer."ADAMFEUERSTEIN/STATYou’rereadingthewebeditionofASCOin30Seconds,STAT’sguidetotheAme